Cross-senolytic effects of dasatinib and quercetin in humans

Introduction: Senescent cells are toxic cells. Their number increases every day and after some time it leads to the appearance of signs of aging. Senescent cells cause age-related pathologies. Objective: Simultaneous administration of dasatinib and quercetin in Ercc1-/∆ mice resulted in the partial killing of senolytic cells and improved and prolonged health, age-related symptoms and pathologies. We decided to test the senolytic effect of the combination of dasatinib and quercetin in humans. Study Design: A clinical study was conducted on 64 male volunteers aged 36 years and older. Our volunteers were divided into 4 groups, each with 16 people. The D+Q group received 50 mg dasatinib and 500 mg quercetin together once daily for 5 days. Other groups: D+P - dasatinib + placebo group; Q+P – quercetin + placebo group; P+P – placebo (dasatinib) + placebo (quercetin) group. Methods: The study was completed by screening a blood count and a stair ascending test to register and evaluate the changes. Results: Co-administration of 50 mg dasatinib with 500 mg quercetin showed a clear senolytic effect. This was confirmed by the improved results of the stair ascending test. A general blood test showed that the combination of these two drugs in such a dosage is most likely to be harmless. Conclusion: These results demonstrate the possibility of selective elimination of senescent cells in humans and the effectiveness of senolytic agents in improving health and physical performance.